Skip to main content
SpringerLink
Log in

Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure

  • Original Article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Introduction

Although hypertensive drugs may have the same effect on peripheral blood pressure, they vary in their effect on central blood pressure and its indices.

Aim

To evaluate efficacy of fixed-dose combination of amlodipine 10 mg/valsartan 160 mg versus nebivolol 5 mg/valsartan 160 mg in grade 2 or more hypertensive patients assessed by peripheral and central blood pressure.

Methods

A prospective, open label, randomized study done in the outpatient cardiology clinic at Beni-Suef University Hospital. A total of 137 patients continued the study; group I (n = 75) received Amlodipine 10 mg/Valsartan 160 mg (A/V) and group II (n = 62) received Nebivolol 5 mg/Valsartan 160 mg (N/V). Peripheral, central blood pressure and its indices were measured at baseline, after 6 and 12 weeks.

Results

The two combinations reduced peripheral and central BP (P < 0.0001) after 6 and 12 weeks. A/V combination significantly reduces central Pulse Pressure (PP) after 6 and 12 weeks (− 8.53 ± 13.80 and − 10.17 ± 11.29 (P < 0.0001) respectively), while N/V showed its efficacy in reducing central PP after 12 weeks (− 7.03 ± 13.10, P = 0.005). A/V combination was more effective in reducing Pulse Wave Velocity (PWV) after 6 and 12 weeks; P < 0.0001 vs P = 0.004. After 6 weeks, N/V was more effective in reducing Augmentation Index (AIx) (− 6.00 ± 10.94 (P = 0.002) vs. − 3.44 ± 9.80 (P = 0.026)) while after 12 weeks A/V did not show any significance (P = 0.085).

Conclusions

Both treatment groups lowered patients’ peripheral, central blood pressure after 6 and 12 week of treatment, but Amlodipine/Valsartan combination was more effective. Both treatments exerted different effects on central indices.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77(9):1279–86.

    PubMed  Google Scholar 

  2. Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38.

    Article  CAS  Google Scholar 

  3. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248.

  4. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.

    Article  CAS  PubMed  Google Scholar 

  5. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50(1):197–203.

    Article  CAS  PubMed  Google Scholar 

  6. Vlachopoulos C. Combination therapy in hypertension: from effect on arterial stiffness and central haemodynamics to cardiovascular benefits. Artery Res. 2016;14:27–35.

    Article  Google Scholar 

  7. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5:353–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.

    Article  PubMed  Google Scholar 

  9. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35(26):1719–25.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC, et al. Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension. 2011;58(5):825–32.

    Article  CAS  PubMed  Google Scholar 

  11. Smith Timothy R, Philipp Thomas, Vaisse Bernard, Bakris George L, Wernsing Margaret, Yen Joseph, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9:355–64.

    Article  CAS  Google Scholar 

  12. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563–80.

    Article  CAS  PubMed  Google Scholar 

  13. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens. 2013;15(3):193–200.

    Article  CAS  Google Scholar 

  14. Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens. 2013;15(4):270–8.

    Article  CAS  Google Scholar 

  15. Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens. 2012;14(9):588–92.

    Article  CAS  Google Scholar 

  16. Ishak J, Rael M, Punzi H, Gradman A, Anderson LM, Patel M, et al. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension. J Clin Hypertens. 2018;20(1):143–9.

    Article  CAS  Google Scholar 

  17. Neutel JM, Giles TD, Punzi H, Weiss RJ, Li H, Finck A. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. JASH. 2014;8(12):915–20.

    CAS  PubMed  Google Scholar 

  18. Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013;30(12):1086–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Vaz-de-Melo OR, Giollo-Júnior TL, Martinelli DD, et al. Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study. Sao Paulo Med J. 2014;132(5):290–296.

    Article  PubMed  Google Scholar 

  20. Dhakam Z, McEniery CM, Brown MJ, Wilkinson AIB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26(2):351–6.

    Article  CAS  PubMed  Google Scholar 

  21. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57(6):1122–8.

    Article  CAS  PubMed  Google Scholar 

  22. Boutouyrie P, Beaussier H, Achouba A, Laurent S, Trialists E. Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. J Hyperten. 2014;32(1):108–14.

    Article  CAS  Google Scholar 

  23. Boutouyrie P, Achouba A, Trunet P, Laurent S, Group ET. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55(6):1314–22.

    Article  CAS  PubMed  Google Scholar 

  24. Studinger P, Tabak AG, Chen CH, Salvi P, Othmane TE, Torzsa P, et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens. 2013;15(12):910–7.

    Article  CAS  Google Scholar 

  25. Shi R, Liu K, Shi D, Liu Q, Chen X. Effects of amlodipine and valsartan on blood pressure variability and pulse wave velocity in hypertensive patients. Am J Med Sci. 2017;353(1):6–11.

    Article  PubMed  Google Scholar 

  26. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21(6):663–7.

    Article  CAS  PubMed  Google Scholar 

  27. Fogari R, Zoppi A, Derosa G, Mugellini A, Lazzari P, Rinaldi A, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220–4.

    Article  CAS  PubMed  Google Scholar 

  28. Weiss RJ, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2013;13(2):129–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Department, Beni-Suef Hospital University, Beni-Suef, Egypt

    Selvia M. Farag

  2. Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt

    Hoda M. Rabea

  3. Beni-Suef Hospital University, Beni-Suef, Egypt

    Hesham B. Mahmoud

Authors
  1. Selvia M. Farag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hoda M. Rabea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hesham B. Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Selvia M. Farag.

Ethics declarations

Ethical approval

The study was approved by Faculty of Medicine - Beni-Suef University Research Ethical Committee “FM-BSU REC” and was registered (FWA00015574).

Informed consent

Informed consent was obtained from each patient before participation in the trial.

Conflict of interest

We declare that we have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farag, S.M., Rabea, H.M. & Mahmoud, H.B. Effect of Amlodipine/Valsartan Versus Nebivolol/Valsartan Fixed Dose Combinations on Peripheral and Central Blood Pressure. High Blood Press Cardiovasc Prev 25, 407–413 (2018). https://doi.org/10.1007/s40292-018-0286-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-018-0286-8

Keywords

Search

Navigation